Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Microsoft

- PMLiVE

Almirall set to participate in Innovative Medicines Initiative’s FACILITATE project

The project aims to return clinical trial data to participants, readying it for reuse in future research

- PMLiVE

ICR and The Royal Marsden reveal plans to ‘disrupt’ cancer ecosystems

The researchers aim to double survival for people with advanced cancer within a decade

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Best practice in UK dermatology care celebrated at second national awards

NHS teams from the Isle of Wight, Northern Ireland and London were among those recognised at the second annual Quality in Care Dermatology Awards

- PMLiVE

Dermavant’s Vtama shows promise in paediatric atopic dermatitis trial

The trial included children aged between two to 17 years and the treatment was well tolerated

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing AI and behavioral science to personalize each user’s health journey, and how this approach can help improve diversity...

Impetus Digital

- PMLiVE

Verge Genomics begins human trials with AI-sourced ALS drug

VRG50635 was discovered by the company’s all-in-human, AI-powered platform

- PMLiVE

Almirall granted EMA approval for lebrikizumab in atopic dermatitis

The Marketing Authorization Application is based on three pivotal phase 3 studies

- PMLiVE

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Research Partnership

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

Incyte’s Opzelura shows significant improvements in phase 3 vitiligo trial

The positive data has been published in The New England Journal of Medicine

- PMLiVE

Seeing AI app launched by Haleon and Microsoft to enhance sight accessibility

The app is free to download from the Apple App Store and will be available on Android in the future

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links